Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Boehringer launches iPhone app for patients on Gilotrif

App offers treatment guide for those taking its cancer drug

Boehringer Ingelheim Gilotrif iPhone appBoehringer Ingelheim has released an iPhone app for patients prescribed its cancer drug Gilotrif (afatinib).

The My Treatment Guide app offers tools such as a medication reminder alarm, diary and calendar to keep track of appointments - all fairly standard tools for this type of app.

More unusually though it also includes branded information about Gilotrif and on what to expect during treatment with the drug.

The app, which doesn't yet appear to be available in an Android version, also provides 'discussion topics' for a patient's visits to their doctor and links to patient support sites.

Launched in the US in 2013, Gilotrif was Boehringer's first cancer drug to reach the market following FDA approval for its use in non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations.

The personalised cancer drug was approved alongside a companion diagnostic developed by Qiagen to detect the presence of EGFR mutations.

Boehringer said at the time that it planned to support the Gilotrif's launch with a “comprehensive patient support programme” of services.

29th May 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics